How did you decide to participate in the Biomapas Academy?
The first thing that caught my attention was the Biomapas Academy poster hanging on my university’s bulletin board. Shortly afterwards, the faculty management shared Biomapas’ invitation to register for the first Biomapas Academy. I wanted to learn more about this company, so I decided to take my chances and apply to the Academy. I was thrilled when I received a call with the happy news that I had successfully passed the selection process and was invited to attend the Academy.
What was your experience during the three months?
I listened to many interesting lectures, during which we got to know the company and its areas of activity. We listened to lectures on clinical trials and their organization, pharmacovigilance, regulatory affairs, bioethics, drug registration, and more. I believe that the knowledge gained at the Academy is valuable and helpful for all participants of the Academy and their future careers.
What did the future hold for you after the Academy?
I mainly was interested in pharmacovigilance, so we agreed on an internship in this department during the summer. Interesting fact: the first Biomapas poster I saw was about pharmacovigilance! And the best thing is that after the internship, I was able to join and become a part of this great team. I am happy to be here and to learn from real professionals in this field.
What would you say to the future participants?
I want to encourage everyone who is thinking about participating in the Biomapas Academy. Being at the Academy is exciting and worthwhile. By joining the Academy, you will broaden your horizons, learn from global professionals, improve your life sciences knowledge, and gain valuable experience. I wish good luck to all participants. See you soon at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
When Do Biotech Companies and Startups Need Pharmacovigilance
Many biotech startups assume pharmacovigilance begins after approval, but regulatory expectations and clinical trial complexity often require safety oversight much earlier. Learn when pharmacovigilance becomes essential and how to stay compliant as you scale.
How to Build Clinical Safety for Biotechs Without a Full Department
Discover how biotech companies can build scalable clinical safety management early, ensuring compliance, oversight, and efficient operations across development phases.
Biomapas Insights: Navigating Italian Regulatory Requirements and AIFA Updates
Clear guidance on Italian regulatory requirements for promotional materials and recent AIFA updates affecting pharmaceutical companies.
Clinical Safety Management in Pharma: How to Manage Risk Across the Drug Development Lifecycle
Learn how effective clinical trial safety management supports risk mitigation, regulatory compliance, and patient safety across all stages of drug development.
Global Case Processing in Pharmacovigilance: Practical Guide to Compliance, Quality, and Scale
As pharmacovigilance expands across markets, maintaining control becomes challenging. In this article, we explore key risks, regulatory differences, and scalable models for global case processing.
Case Study: International & Local Pharmacovigilance/Medical Information Services – Urgent Action
Discover how Biomapas delivered a seamless global and local transition for a pharmaceutical company, facing a critical Pharmacovigilance and Medical Information vendor transition with a non‑negotiable one‑month timeline.
Marketing Pharmaceutical Products in CIS/Eurasian Economic Union
Explore how pharmaceutical companies can successfully market products in CIS and EAEU countries, highlighting regulatory differences from the EU, recent legislative changes, and practical RA and pharmacovigilance considerations.
Partial Pharmacovigilance Outsourcing: A Scalable Approach for Biopharma
Learn how partial pharmacovigilance outsourcing helps biopharma maintain oversight while scaling resources effectively.
Pharmacovigilance and Medical Information Outsourcing: Benefits for Biotech
Learn how PV and MI outsourcing enables biotechs to reduce costs, scale efficiently, strengthen compliance, and accelerate market readiness.
Biomapas Insights: Clinical Site Selection for Early Phase Oncology Studies
Expert perspectives on where to begin, how to choose the right clinical sites, and what to consider when selecting an eCRF/EDC system for early-phase oncology studies.
